Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KRAS G12D mutant protein is a variant of the KRAS protein, a small GTPase that plays a central role in cell signaling pathways regulating proliferation, differentiation, and survival. The G12D mutation impairs intrinsic GTPase activity, leading to constitutive activation of KRAS signaling. This promotes uncontrolled cellular proliferation, drives transformation of normal epithelial cells into malignant ones, enhances invasion and metastasis capabilities, and increases resistance to apoptosis. G12D is especially common in pancreatic cancer but also found across NSCLC. Direct targeting has been historically difficult, but recent advances include engineered proteins or peptides that exploit unique features introduced by the mutation, and small-molecule inhibitors targeting S-II pocket are under clinical investigation.
Inhibition of KRAS(G12D) activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kirsten rat sarcoma viral oncogene homolog (KRAS) – Glycine 12 Aspartate mutant (KRAS(G12D)).